In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
Executive Summary
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
You may also be interested in...
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
The U.S. biotechs, which are independent but share founders and investors, raise a combined $94.5 million from the Russian sovereign fund and U.S. venture firms.
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
Selecta Biosciences Inc. and BIND Biosciences Inc., two Boston-based -- and heretofore low-profile -- young biotechs, have raised a combined $94.5 million from a mix of equity financings and strategic alliances with one of the world's largest investment funds dedicated to nanotechnology, Rusnano, and other investors
Aura Biosciences Prepares To Move Nano-Enabled Drug Delivery System Into The Clinic
Biotech's nanotechnology platform enables earlier detection of cancers and distant metastases, as well as targeted drug delivery.